Please login to the form below

Not currently logged in
Email:
Password:

STEM

This page shows the latest STEM news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs J&J’s new-class antidepressant

FDA panel backs J&J’s new-class antidepressant

The FDA’s willingness to accept a lower level of efficacy evidence likely stems from the pressing need for additional treatment options for treatment-resistant MDD, which is associated with a

Latest news

More from news
Approximately 15 fully matching, plus 345 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The analysts predict the drug will be priced at around $550, 000 (472, 000) per treatment, a level that compares favourably with the cost of conventional stem cell therapy of $500,

  • Brand teams: why are some smarter than others? Brand teams: why are some smarter than others?

    They stem from different philosophies of knowledge. They take as their inputs different kinds of information from different sources.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Raju Prasad says Bluebird can offer a compelling cost-effectiveness case for its treatment in beta thalassemia and sickle cell cases versus conventional stem cell treatment. ... Conventional stem cell transplants cost anywhere between $500, 000 and $1m,

  • 30 Women Leaders in UK Healthcare (part 3) 30 Women Leaders in UK Healthcare (part 3)

    Kathy Niakan is a group leader at London's academic research hub The Francis Crick Institute.and is investigating the mechanisms of lineage specification in human embryos and stem cells. ... of infertility, miscarriages and developmental disorders, and

  • Reaching the new influencers Reaching the new influencers

    Right now, we’re living through healthcare’s age of accelerations - as evidenced by advances in everything from biotechnology and stem cell research to machine learning and the advent (and approvals)

More from intelligence
Approximately 1 fully matching, plus 49 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader.

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

  • Simon Doyle joins STEM Simon Doyle joins STEM

    Benchmarking company STEM has appointed Simon Doyle as its new vice president of global customer relations and development. ... further drive value to STEM’s clients.

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.

  • Porterhouse Medical promotes Emma Conran Porterhouse Medical promotes Emma Conran

    Conran has served in medical writing positions at Porterhouse Medical since 2014 and prior to that she was a translational stem cell biology lecturer at King’s College London.

More from appointments
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics